Comparison of the biodistribution in mice of 111Indium oxine encapsulated into poly(lactic-co-glycolic)-D,L-85/15 and poly(epsilon caprolactone) nanocapsules

Journal of Pharmaceutical Sciences

Volumn 88, Issue 4, 1999, Pages 450-453

  Marchal Heussler, L ^a   Thouvenot, P ^b   Hoffman, M ^c   Maincent, P ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

8 QUINOLINOL INDIUM IN 111; COPOLYMER; NANOCAPSULE; POLYCAPROLACTONE; POLYGLACTIN;

ANIMAL EXPERIMENT; ARTICLE; DRUG DISTRIBUTION; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MALE; MICROENCAPSULATION; MOUSE; NONHUMAN; PARTICLE SIZE; RADIOACTIVITY;

EID: 0032929707     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js980307k     Document Type: Article

References (21)

1. Fawaz, F.; Bonini, F.; Guyot, M.; Lagueny, A. M.; Fessi, H.; Devissaguet. J. P. Influence of poly(DL-lactide) nanocapsules on the biliary clearance and enterohepatic circulation of indomethacin in the rabbit. Pharm. Res. 1993, 10, 750-756.
2. Marchal-Heussler, L.; Sirbat, D.; Hoffman, M.; Maincent, P. Poly(epsilon-caprolactone) nanocapsules in carteolol ophthalmic delivery. Pharm. Res. 1993, 10, 386-390.
3. Kiwada, H. Plasma factors affecting disposition of liposomes. Adv. Drug. Del. Rev. 1997, 24, 193-199.
4. Bazile, D.; Prudihomme, C.; Bassoullet, M. T.; Marlard, M.; Spenlehauer, G.; Veillard, M. Stealth MePEG-PLA nanoparticles avoid uptake by mononuclear phagocytes system. J. Pharm. Sci. 1995, 84, 493-498.
5. Simon, B. H.; Ando, H. Y.; Gupta, P. K. Circulation time and body distribution of C14-labeled amino-modified polystyrene nanoparticles in mice. J. Pharm. Sci. 1995, 84, 1249-1253.
6. Bonduelle, S.; Pimienta, C.; Benoit, J. P.; Lenaerts, V. Body distribution in mice of intravenously injected radiolabeled cyclosporin associated with polyisohexylcyanpacrylate nanocapsules or nanospheres. Eur. J. Pharm. Biopharm. 1995, 41, 27-30.
7. Scherphof, G. L. Modulation of pharmacokinetic behavior of liposomes. Adv. Drug. Del. Rev. 1997, 24, 179-191.
8. Rolland, A.; Collet, B.; Le Verge, R.; Toujas, L. Blood clearance and organ distribution of intravenously administered polymethacrylic nanoparticles in mice. J. Pharm. Sci. 1989, 78, 481-484.
9. Gahnem, G. E.; Joubran, C.; Arnould, R.; Lejeune, F.; Fruhling, J. Labeled polycyanoacrylate nanoparticles for human in vivo use. Appl. Radiat. Isot. 1993, 44, 1219-1224.
10. Thanoo B. C.; Doll W. J.; Metha R. C.; Digenis, G. A.; Deluca, P. P. Biodegradable indium-111 labeled microspheres for in vivo evaluation of distribution and elimination. Pharm. Res. 1995, 12, 2060-2064.
11. Kreuter, J.; Wilson, C. G.; Fry, J. R.; Paterson, P.; Ratcliffe, J. H. Toxicity and association of polycyanoacrylate nanoparticles with hepatocytes. J. Microencapsul. 1984, 1, 253-257.
12. Fessi, H.; Puisieux, F.; Devissaguet, J. P.; Ammoury, N.; Benita, S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 1989, 55, R1-R4.
13. Ammoury, N.; Fessi, H.; Devissaguet, J. P.; Dubrasquet, M.; Benita, S. Jejunal absorption, pharmacological activity and pharmacokinetic evaluation of indomethacin-loaded poly(d,1-lactide) and poly(isobutyl-cyanoacrylate) nanocapsules in rats. Pharm. Res. 1991, 8, 101-105.
14. Kedzierewicz, F.; Thouvenot, P.; Monot, I.; Hoffman, M.; Maincent, P. Influence of different physicochemical conditions on the release of indium oxine from nanocapsules. J. Biomed. Mater. Res. 1998, 30, 588-593.
15. Lescure, F.; Seguin, C.; Breton, P.; Bourrinet, P.; Roy, D.; Couvreur, P. Preparation and characterization of novel poly-(methylidene malonate 2.1.2.)-made nanoparticles. Pharm. Res. 1994, 11, 1270-1277.
16. Tan, J. S.; Butterfield, D. E.; Voycheck, C. L.; Caldwell, K. D.; Li, J. T. Surface modification of nanoparticles by PEO/ PPO block copolymers to minimize interactions with blood components and prolong blood circulation in rats. Biomaterials 1993, 14, 823-833.
17. Sahli, H.; Japon-Bretandière, J.; Fischer, A. M.; Sternberg, C.; Spenlehauer, G.; Verrechia, T.; Labarre, D. Interactions of poly(lactic acid) and poly(lactic acid-co-ethylene oxide) nanoparticles with the plasma factors of coagulation system. Biomaterials 1997, 18, 281-288.
18. Borchard, G.; Kreuter, J. The role of serum complement on the organ distribution of intravenously administered poly-(methyl methacrylate) nanoparticles: effect of precoating with plasma and with serum complement. Pharm. Res. 1996, 13, 1055-1058.
19. Blunk, T.; Hochstrasser, D. F.; Sanchez, J. C.; Muller, B. W.; Muller, R. H. Colloidal carriers for intravenous drug targeting: plasma protein adsorption patterns on surface-modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 1993, 14, 1382-1387.
20. Stolnik, S.; Dunn, S. E.; Garnett, M. C.; Davies, M. C.; Coombes, A. G. A.; Taylor, D. C.; Irwing, M. P.; Purkiss, S. C.; Tadros, T. F.; Davis, S. S.; Illum, L. Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers. Pharm. Res. 1994, 11, 1800-1808.
21. Alyantdin, R. N.; Petrov, V. E.; Langer, K.; Berthold, A.; Kharbevich, D. A.; Kreuter, J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm. Res. 1997, 14, 325-328.